Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. weekly Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E30.36 EPS (ttm)19.90 Insider Own19.40% Shs Outstand109.80M Perf Week11.08%
Market Cap64.16B Forward P/E19.14 EPS next Y31.57 Insider Trans-3.90% Shs Float84.27M Perf Month11.53%
Income2.28B PEG3.62 EPS next Q6.18 Inst Own69.90% Short Float2.11% Perf Quarter22.45%
Sales7.98B P/S8.04 EPS this Y-10.80% Inst Trans2.22% Short Ratio1.11 Perf Half Y65.07%
Book/sh110.50 P/B5.47 EPS next Y16.24% ROA15.80% Target Price531.50 Perf Year100.05%
Cash/sh37.71 P/C16.03 EPS next 5Y8.40% ROE21.00% 52W Range271.37 - 618.71 Perf YTD60.94%
Dividend- P/FCF37.62 EPS past 5Y44.00% ROI16.10% 52W High-2.33% Beta0.54
Dividend %- Quick Ratio3.70 Sales past 5Y22.80% Gross Margin89.70% 52W Low122.68% ATR24.74
Employees8100 Current Ratio4.20 Sales Q/Q33.20% Oper. Margin30.50% RSI (14)60.14 Volatility5.13% 3.93%
OptionableYes Debt/Eq0.06 EPS Q/Q35.90% Profit Margin28.60% Rel Volume0.96 Prev Close617.66
ShortableYes LT Debt/Eq0.06 EarningsMay 05 BMO Payout0.00% Avg Volume1.60M Price604.28
Recom2.20 SMA205.73% SMA5012.75% SMA20051.79% Volume1,534,652 Change-2.17%
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
May-23-19Resumed Citigroup Neutral
Jun-03-20 05:02PM  
03:13PM  
11:42AM  
09:56AM  
06:25AM  
06:13AM  
Jun-02-20 01:49PM  
11:09AM  
11:00AM  
10:53AM  
09:15AM  
08:00AM  
03:07AM  
02:35AM  
Jun-01-20 04:37PM  
12:12PM  
11:46AM  
09:57AM  
07:57AM  
07:00AM  
06:07AM  
May-30-20 11:17AM  
May-29-20 08:59PM  
04:01PM  
11:40AM  
11:27AM  
11:13AM  
09:37AM  
08:53AM  
08:00AM  
May-28-20 12:20PM  
11:34AM  
11:26AM  
11:13AM  
08:14AM  
05:54AM  
May-27-20 10:35AM  
10:08AM  
09:47AM  
09:07AM  
06:27AM  
05:16AM  
01:28AM  
May-26-20 11:19PM  
07:55PM  
04:34PM  
01:50PM  
12:06PM  
11:39AM  
10:41AM  
09:55AM  
09:03AM  
08:44AM  
07:54AM  
06:54AM  
06:48AM  
02:49AM  
May-25-20 10:04PM  
03:05PM  
01:20PM  
12:40PM  
03:26AM  
May-24-20 02:40PM  
May-22-20 06:47PM  
May-21-20 03:48PM  
02:49PM  
May-19-20 08:03AM  
May-18-20 05:28PM  
May-15-20 03:43PM  
01:23PM  
11:20AM  
May-14-20 01:46PM  
01:27PM  
11:51AM  
11:16AM  
May-13-20 10:32AM  
08:16AM  
May-12-20 07:52AM  
May-11-20 11:13PM  
07:00AM  
06:34AM  
May-10-20 02:02PM  
May-09-20 02:19PM  
May-08-20 06:16PM  
04:53PM  
02:46PM  
09:25AM  
May-07-20 09:59AM  
09:41AM  
May-06-20 05:18PM  
12:55PM  
09:10AM  
May-05-20 11:31PM  
04:21PM  
04:18PM  
04:11PM  
04:11PM  
04:02PM  
03:31PM  
03:22PM  
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. It also has a strategic collaboration with Zai Lab Limited. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RYAN ARTHUR FDirectorJun 01Sale603.2310060,32328,743Jun 02 04:04 PM
SING GEORGE LDirectorMay 29Sale596.511,000596,5102,400Jun 01 04:08 PM
SING GEORGE LDirectorMay 28Sale579.001,000579,0002,900Jun 01 04:08 PM
GOLDSTEIN JOSEPH LDirectorMay 28Sale578.941,000578,9406,643Jun 01 04:02 PM
VAGELOS P ROYChairman of the BoardMay 21Sale577.49783452,178307,749May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 21Sale564.37148,81183,984,786308,532May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 20Option Exercise30.63312,5009,571,875497,063May 22 06:21 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 15Sale572.008,3804,793,36014,438May 15 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 14Option Exercise59.2018,3111,084,01132,749May 15 04:03 PM
SING GEORGE LDirectorMay 13Option Exercise33.425,000167,100120,415May 13 09:00 PM
SING GEORGE LDirectorMay 13Sale580.005,0002,900,000115,415May 13 09:00 PM
SCHLEIFER LEONARD SPresident & CEOMay 12Sale569.22150,92285,908,042474,499May 13 09:01 PM
SCHLEIFER LEONARD SPresident & CEOMay 11Option Exercise30.63312,5009,571,875722,368May 13 09:01 PM
SING GEORGE LDirectorMay 11Sale575.00850488,7502,150May 13 09:00 PM
STAHL NEILEVP Research and DevelopmentMay 11Sale569.525,3053,021,28911,380May 11 04:39 PM
STAHL NEILEVP Research and DevelopmentMay 08Option Exercise52.0312,500650,37523,880May 11 04:39 PM
Zoghbi Huda YDirectorMay 07Option Exercise391.925,1182,005,8475,761May 08 04:03 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 07Sale564.3239,58322,337,30628,251May 08 04:04 PM
Zoghbi Huda YDirectorMay 07Sale566.525,1182,899,461643May 08 04:03 PM
BROWN MICHAEL SDirectorMay 07Sale562.001,8091,016,658643May 07 04:14 PM
BROWN MICHAEL SDirectorMay 06Option Exercise371.985,4702,034,7395,863May 07 04:14 PM
Tessier-Lavigne MarcDirectorMay 06Option Exercise177.8215,0002,667,30016,830May 08 04:03 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 06Option Exercise52.0385,5794,452,67596,051May 08 04:04 PM
RYAN ARTHUR FDirectorMay 06Option Exercise373.6750,12418,729,67078,967May 07 06:22 PM
RYAN ARTHUR FDirectorMay 06Sale550.8850,12427,612,50928,843May 07 06:22 PM
GOLDSTEIN JOSEPH LDirectorMay 06Sale560.002,0001,120,0007,643May 06 04:19 PM
Tessier-Lavigne MarcDirectorMay 06Sale563.9715,0008,459,4961,830May 08 04:03 PM
RYAN ARTHUR FDirectorMay 01Sale520.3710052,03728,843May 04 04:02 PM
Landry Robert EEVP Finance CFOApr 20Sale566.943,2501,842,53924,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale570.301,7781,013,98514,438Apr 20 07:27 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale565.483,5221,991,61116,216Apr 20 07:26 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 17Option Exercise59.2011,622688,02222,458Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 17Option Exercise272.7012,5003,408,75036,873Apr 20 07:29 PM
Landry Robert EEVP Finance CFOApr 17Sale557.68991552,66124,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 17Sale557.382,2671,263,58614,438Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 16Option Exercise272.704,0001,090,80028,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 16Option Exercise59.205,000296,00019,438Apr 20 07:26 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 15Sale518.212,2621,172,18714,438Apr 16 04:04 PM
Landry Robert EEVP Finance CFOApr 15Sale518.49853442,27624,373Apr 16 04:03 PM
Landry Robert EEVP Finance CFOApr 14Option Exercise272.703,500954,45027,873Apr 16 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 14Option Exercise59.205,000296,00019,438Apr 16 04:04 PM
STAHL NEILEVP Research and DevelopmentApr 14Sale521.075,4972,864,30711,380Apr 15 04:17 PM
STAHL NEILEVP Research and DevelopmentApr 13Option Exercise52.0313,079680,50024,459Apr 15 04:17 PM
Landry Robert EEVP Finance CFOApr 13Sale509.79828422,10824,373Apr 13 07:23 PM
Landry Robert EEVP Finance CFOApr 09Option Exercise272.703,500954,45027,873Apr 13 07:23 PM
Landry Robert EEVP Finance CFOApr 07Sale497.52696346,27124,373Apr 08 04:02 PM
Landry Robert EEVP Finance CFOApr 06Option Exercise272.703,000818,10027,373Apr 08 04:02 PM
Landry Robert EEVP Finance CFOApr 03Sale494.28683337,59224,373Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Option Exercise272.703,000818,10028,726Apr 03 04:49 PM
Landry Robert EEVP Finance CFOApr 02Sale495.8810552,06825,056Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Sale489.321,248610,67225,161Apr 03 04:49 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 02Sale489.986,7973,330,40614,438Apr 03 04:08 PM
Fenimore Christopher R.VP ControllerApr 01Option Exercise30.631,20036,75614,297Apr 03 04:05 PM
Landry Robert EEVP Finance CFOApr 01Option Exercise272.706,0001,636,20026,937Apr 03 04:49 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 01Option Exercise59.2015,000888,00023,924Apr 03 04:08 PM
Landry Robert EEVP Finance CFOApr 01Sale488.02600292,81124,373Apr 03 04:49 PM
Fenimore Christopher R.VP ControllerApr 01Sale488.411,200586,09613,097Apr 03 04:05 PM
RYAN ARTHUR FDirectorApr 01Sale483.8510048,38528,943Apr 01 06:49 PM
RYAN ARTHUR FDirectorMar 30Sale466.6910046,66929,043Apr 01 06:49 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 10Sale470.47117,81555,428,041517,799Mar 11 04:05 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 09Option Exercise30.63246,7367,557,524713,990Mar 11 04:05 PM
GOLDSTEIN JOSEPH LDirectorMar 09Option Exercise33.422,00066,84011,643Mar 10 04:05 PM
GOLDSTEIN JOSEPH LDirectorMar 09Sale475.842,000951,6849,643Mar 10 04:05 PM
STAHL NEILEVP Research and DevelopmentFeb 27Sale452.2610,3494,680,46011,380Feb 28 04:40 PM
SING GEORGE LDirectorFeb 26Option Exercise33.422,50083,550117,915Feb 28 04:30 PM
STAHL NEILEVP Research and DevelopmentFeb 26Option Exercise52.0325,0001,300,75036,380Feb 28 04:40 PM
Landry Robert EEVP Finance CFOFeb 26Sale456.2120091,24224,973Feb 26 06:14 PM
Van Plew Daniel PEVP & General Mgr Industrial OFeb 26Sale457.2315,6427,152,01628,251Feb 27 04:12 PM
SING GEORGE LDirectorFeb 26Sale460.002,5001,150,000115,415Feb 28 04:30 PM
SING GEORGE LDirectorFeb 26Sale452.832,4001,086,8002,400Feb 28 04:30 PM
Van Plew Daniel PEVP & General Mgr Industrial OFeb 25Option Exercise30.6332,7351,002,67360,986Feb 27 04:12 PM
Landry Robert EEVP Finance CFOFeb 25Option Exercise272.701,000272,70026,187Feb 26 06:14 PM
Landry Robert EEVP Finance CFOFeb 25Sale449.0121496,08825,173Feb 26 06:14 PM
Landry Robert EEVP Finance CFOFeb 24Option Exercise272.701,000272,70025,973Feb 26 06:14 PM
BROWN MICHAEL SDirectorFeb 24Option Exercise273.672,000547,3402,643Feb 25 04:03 PM
BROWN MICHAEL SDirectorFeb 24Sale419.002,000838,001643Feb 25 04:03 PM
YANCOPOULOS GEORGEPresident and Chief ScientificFeb 24Sale420.17118,12349,631,741517,799Feb 25 04:05 PM
Tessier-Lavigne MarcDirectorFeb 13Option Exercise53.0814,279757,94411,109Feb 14 04:10 PM
Tessier-Lavigne MarcDirectorFeb 13Sale400.0114,2795,711,7111,830Feb 14 04:10 PM
Landry Robert EEVP Finance CFOFeb 13Sale400.0510742,80624,973Feb 14 04:10 PM
Landry Robert EEVP Finance CFOFeb 12Option Exercise272.70500136,35025,473Feb 14 04:10 PM
GOLDSTEIN JOSEPH LDirectorFeb 07Sale382.831,000382,8309,643Feb 10 04:45 PM
MURPHY ANDREW JEVP ResearchJan 27Sale340.918,0002,727,27949,951Jan 28 05:06 PM
Fenimore Christopher R.VP ControllerJan 24Option Exercise30.6350015,31513,097Jan 27 04:04 PM
SING GEORGE LDirectorJan 02Option Exercise24.4115,000366,150130,095Jan 06 04:02 PM
SING GEORGE LDirectorJan 02Sale371.9815,0005,579,700115,095Jan 06 04:02 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise30.6340012,25212,597Dec 23 04:02 PM
BROWN MICHAEL SDirectorDec 13Option Exercise273.674,0001,094,6804,323Dec 13 04:07 PM
BROWN MICHAEL SDirectorDec 13Sale373.994,0001,495,968323Dec 13 04:07 PM
Fenimore Christopher R.VP ControllerDec 13Sale376.141,682632,66512,197Dec 13 06:03 PM
VAGELOS P ROYChairman of the BoardDec 13Sale376.0451,84219,494,489304,485Dec 13 05:43 PM
VAGELOS P ROYChairman of the BoardDec 12Option Exercise21.25107,6552,287,669412,140Dec 13 05:43 PM
YANCOPOULOS GEORGEPresident and CSODec 12Option Exercise21.25245,2955,212,519521,876Dec 13 04:44 PM
SCHLEIFER LEONARD SPresident & CEODec 12Option Exercise21.25312,4006,638,500571,708Dec 13 04:05 PM
Fenimore Christopher R.VP ControllerDec 12Option Exercise52.033,100161,29315,297Dec 13 06:03 PM
GOLDSTEIN JOSEPH LDirectorNov 27Option Exercise33.421,00033,42011,323Dec 02 04:03 PM
GOLDSTEIN JOSEPH LDirectorNov 27Sale370.001,000370,00010,323Dec 02 04:03 PM
STAHL NEILEVP Research and DevelopmentNov 26Sale364.074,0061,458,46722,455Nov 26 04:29 PM
STAHL NEILEVP Research and DevelopmentNov 25Option Exercise52.0310,000520,30032,455Nov 26 04:29 PM
VAGELOS P ROYChairman of the BoardNov 25Sale363.8722,1498,059,412304,485Nov 26 04:02 PM